Browse
Submit Data
Databases
API
Help

Dataset Information

15 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Observational study of XELOX in combination with bevacizumab for advanced or recurrent colorectal cancer

ABSTRACT: Interventions: Oxaliplatin 130mg/m2 i.v.(day1) Bevacizumab 7.5mg/kg i.v.(day1) Capecitabine 2000mg/m2 p.o.(day1-14) to be repeated every 3weeks Primary outcome(s): Overall response rate Study Design: Single arm Non-randomized

DISEASE(S): Advanced And Recurrent Colorectal Cancer

PROVIDER: 2620414 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A randomized phase II study of XELOX plus Bevacizumab versus XELIRI plus Bevacizumab for advanced colorectal cancer with or without mitochondrial transcription factor A (mtTFA) expression.

Project description:Interventions: mtTFA(+):Oxaliplatin 130mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine2,000mg/m2 p.o.(day1-14) to be repeated every 3 weeks until progression mtTFA(+):Irinotecan 200mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine1,600mg/m2 p.o.(day1-14) to be repeated every 3 weeks until progression mtTFA(-):Oxaliplatin 130mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine2,000mg/m2 p.o.(day1-14) to be repeated every 3 weeks until progression mtTFA(-):Irinotecan 200mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine1,600mg/m2 p.o.(day1-14) to be repeated every 3 weeks until progression Primary outcome(s): Response rate with or without mtTFA expression Study Design: Parallel Randomized

| 2620502 | ecrin-mdr-crc

Clinical efficacy and biomarker assessment of Capecitabine plus oxaliplatin (XELOX) in combination with Bevacizumab as second-line therapy in patients with advanced or recurrent colorectal cancer after failure to irinotecan. Multi-center phase II Study.

Project description:Interventions: Capecitabine plus oxaliplatin (XELOX) in combination with Bevacizumab. Capecitabine:2000mg/m2/day p.o.(day1-15) Oxaliplatin:130mg/m2 i.v.(day1) Bevacizumab:7.5mg/kg i.v.(day1) to be repeated every 3 weeks Primary outcome(s): 6-month Progression free survival rate Study Design: Single arm Non-randomized

| 2620624 | ecrin-mdr-crc

Assessment of clinical efficacy and safety in capecitabine plus intermittent oxaliplatin (intermittent CapeOx)together with Bevacizumab as the first-line therapy for patients with advanced colorectal cancer; multicenter phase II trial

Project description:Interventions: capecitabine plus intermittent oxaliplatin (CapeOx) in combination with Bevacizumab: (CapeOx + Bevacizumab)x5 cycles followed by (Capecitabine + Bevacizumab )x5 cycles, followed by (CapeOx + Bevacizumab)x5 cycles are administered until progression. [CapeOx + Bevacizumab] Capecitabine: 2000mg/m2/day p.o. (day1-15) Oxaliplatin: 130mg/m2 i.v. (day1) Bevacizumab: 7.5mg/kg i.v. (day1) to be repeated every 3 weeks [Capecitabine + Bevacizumab] Capecitabine: 2000mg/m2/day p.o. (day1-15) Bevacizumab: 7.5mg/kg i.v. (day1) to be repeated every 3 weeks Primary outcome(s): progression free survival (PFS) Study Design: Single arm Non-randomized

| 2621169 | ecrin-mdr-crc

Cohort study of XELOX in combination with bevacizumab for unresectable or recurrent colorectal cancer

Project description:Interventions: Oxaliplatin 130mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine X2,000mg/m2, p.o.(day1-14) to be repeated every 3 weeks Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2619370 | ecrin-mdr-crc

Phase II study of early start of chemotherapy after excision of the primary colorectal cancer. (FUTURE 1102-Pearl star 02)

Project description:Interventions: Oxaliplatin 130mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine2,000mg/m2,p.o.(day1-14) to be repeated every 3 weeks Primary outcome(s): Efficacy Study Design: Single arm Non-randomized

| 2621742 | ecrin-mdr-crc

Pilot study of early start of chemotherapy after excision of the primary colorectal cancer. (Pearl star 01)

Project description:Interventions: Oxaliplatin 130mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine2,000mg/m2 p.o.(day1-14) to be repeated every 3 weeks Primary outcome(s): Safety Study Design: Single arm Non-randomized

| 2619811 | ecrin-mdr-crc

A validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone. (AVOID)

Project description:Interventions: Dexamethasone 13.2mg/body i.v.(day1) Oxaliplatin 130mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine2,000mg/m2,p.o.(day1-14) to be repeated every 3 weeks Primary outcome(s): Hypersensitivity reaction incidence Study Design: Single arm Non-randomized

| 2625136 | ecrin-mdr-crc

Clinical study on medical value of adoptive immunotherapy with chemotherapy for stage IV colorectal cancer

Project description:Interventions: Oxaliplatin 130mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine2,000mg/m2,p.o.(day1-14) Autologous alfa/beta T cells i.v. to be repeated every 3 weeks Primary outcome(s): Safety Study Design: Single arm Non-randomized

| 2626285 | ecrin-mdr-crc

A feasibility study of XELOX plus Ca/Mg and Goshajinkigan as adjuvant chemotherapy for colorectal cancer. (KSCC1201)

Project description:Interventions: Oxaliplatin 130mg/m2 i.v. (day1) Capecitabine2,000mg/m2 ,p.o.(day1-14) Ca/Mg 0.8-1g/body i.v. x2 before and after L-OHP infusion (day1) Goshajinkigan 7.5g/body ,p.o.(day1-21) to be repeated every 3 weeks Primary outcome(s): The rate of completion of treatment as planned Study Design: Single arm Non-randomized

| 2623313 | ecrin-mdr-crc

Phase II study of S-1 plus irinotecan combined with bevacizumab as 2nd-line chemotherapy in patients with unresectable colorectal cancer, who had previously received oxaliplatin-based chemotherapy.

Project description:Interventions: CPT-11 150mg/m2 i.v. (day1) Bev 7.5mg/kg i.v. (day1) S-1 80mg/m2 p.o. (day1-14) to be repeated every 3 weeks Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized

| 2621739 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data